Valued at a market cap of $8 billion, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and ...

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets ...

For the quarter ended March 2025, Techne (TECH) reported revenue of $316.18 million, up 4.2% over the same period last year. EPS came in at $0.56, compared to $0.48 in the year-ago quarter.

The market expects Techne (TECH) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook ...

1) Includes the quarterly results of the partially-owned consolidated subsidiary prior to the sale of this partially-owned consolidated subsidiary to a third party in the first fiscal quarter of ...

The latest price target for Bio-Techne (NASDAQ:TECH) was reported by UBS on May 9, 2025. The analyst firm set a price target for $70.00 expecting TECH to rise to within 12 months (a possible 42.86 ...

New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues MINNEAPOLIS, April 24, 2025 /PRNewswire/ -- Bio-Techne ...

MINNEAPOLIS (AP) — MINNEAPOLIS (AP) — Techne Corp. (TECH) on Wednesday reported fiscal third-quarter net income of $22.6 million. The Minneapolis-based company said it had net income of 14 ...